Remove 2018 Remove FDA Remove Prescription Drug Pricing
article thumbnail

Rx 2018: A New Era of Specialty Drugs, Telehealth, Mobile Apps and Value, IQVIA Reports

Health Populi

In 2018, spending on branded prescription drugs will fall in wealthy countries, while spending on specialty drugs will increase, resulting in flat medicines spending. Specifically, $19 billion worth of biotech spending will find biosimilar competition starting in 2018 for the first time. In the U.S.,

article thumbnail

CVS + Aetna: Inflection Point in US Healthcare, Merger Approved Update

Health Populi

This year’s Temkin Experience Index ranked health insurance among the lowest consumer-facing experiences, and Interbrands’ released their 2018 Best Global Brands report this week — which names only a couple of health-focused companies. The Academy convened a team with experience and gravitas to inform this report.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Gap Between the Trump Administration’s Promise of Reducing Rx Costs for Consumers and What People Really Want

Health Populi

This is what happened to pharma stock prices on Friday after President Trump and Secretary of Health and Human Services Alex Azar outlined their new policies focusing on prescription drug prices. Smart Pharmaceuticals Index (NQSSPH) from May 11, 2018, the date when POTUS and Secretary Azar made their announcement.

article thumbnail

Lower Prescription Drug Prices – A Tri-Partisan Call Across America

Health Populi

A new poll jointly conducted by Politico and the Harvard Chan School of Public Health bolsters my read on the latter issue – prescription drug pricing, which has become a mass popular culture union. There may be no other issue on voters’ collective minds for the 2018 mid-term election that so unites American voters.

article thumbnail

In 2023, the U.S. Will Still Be the #1 Prescription Drug Spender in the World, IQVIA Forecasts

Health Populi

paid for prescription drugs in 2018, with roughly four times the number of health citizens. IQVIA rightly calls out digital therapeutics (DTx) in this year’s report, noting the growth of mobile apps and digital tools submitted to the FDA for clearance or approvals. For context and comparison, note that the U.S.